Revvity, Inc. (RVTY) fair value analysis
S&P 500 · Updated 2026-10-19
RVTY price how computed
Forward Fair Value verdict
OvervaluedRVTY is trading at more than a 25% premium to estimated fair value.
Based on TickrTrends' weekly Forward Fair Value model.
- Last price
- $154.18
- Sector
- Healthcare
- 12-month range
- $82.26–$157.36
- Market cap
- $17.2B
- From 52-week high
- -2.0%
- Shares outstanding
- 112M
- Rank in Healthcare by discount to fair value
- #86 of 108
Last price is our 2026-10-19 weekly price; the chart runs through 2026-10-16.
Revvity, Inc. is a healthcare company that provides analytical technologies, software, and services to researchers, clinicians, and diagnosticians across multiple end markets. The company operates globally, serving customers in the life sciences, diagnostics, and applied end markets throughout North America, Europe, Asia-Pacific, and other regions worldwide.
RVTY currently ranks #86 of 108 Healthcare stocks by discount to fair value. It has screened as Overvalued for 6 consecutive weekly runs.
Fundamentals (4 quarters) how computed
- Market cap
- $17.2B
- P/E (trailing)
- 29x
- Revenue (TTM)
- $2.91B
- Net margin
- 8.2%
- EPS (TTM)
- $5.35
- Gross margin
- 57.1%
- Debt / equity
- 0.46
- Revenue growth (3-yr avg)
- 2.9%
- Shares outstanding
- 112M
Derived indicators how computed
- Quality grade
- B
- Margin trend
- Contracting
- 52-week position
- The top quarter of its range
Technicals how computed
- RSI (14-day)
- 55 · neutral
- 50-day average
- $136.12
- 200-day average
- $109.12
- Moving-average state
- 50-day above 200-day (golden cross state); price above both averages
Dividends how computed
- Paid, last 12 months
- $0.21 per share (3 payments)
- Yield on last price
- 0.14%
- Consecutive years of increases
- 0 (no streak on complete calendar years)
- Last ex-dividend date
- 2026-07-17
- Last payment date
- 2026-08-07
Earnings how computed
- Next earnings report
- 2026-11-03 (pre-market)
- Last 8 quarters vs consensus
- 8 beat, 0 missed
- Quarter by quarter
- 2026-06 ▲ beat (+14.6%)
2026-03 ▲ beat (+5.0%)
2025-12 ▲ beat (+7.6%)
2025-09 ▲ beat (+3.5%)
2025-06 ▲ beat (+3.5%)
2025-03 ▲ beat (+6.3%)
2024-12 ▲ beat (+2.9%)
2024-09 ▲ beat (+13.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 5 buy · 11 hold · 1 sell (17 analysts)
- Consensus lean
- Hold-leaning
- Consensus price target
- $148
- Target vs last price
- -4.0%
What our data shows for RVTY
- Our model validated 17 trailing price-to-earnings windows for RVTY, built from quarterly earnings records.
- Shares are trading in the upper third of their 12-month price range of $82.26–$157.36.
- The 14-day relative strength index sits at a neutral 55.
The exact numbers are one step away
- The precise Forward Fair Value dollar figure for RVTY
- Exact discount / premium to today's price
- The normalized historical P/E behind the estimate, and how many quarters support it
- Forward EPS input and fiscal-year basis
- Screeners and rankings across the full S&P 500 and Nasdaq universes
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the RVTY conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — # RVTY Weekly Indicator Summary TickrTrends' derived indicators for RVTY show that the Relative Strength Index moved from overbought territory into neutral zone this week. The stock maintains an overvalued designation according to current valuation metrics within the healthcare sector.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — RVTY has moved into overvalued territory this week, reflecting a shift in its relative valuation position within the healthcare sector. The company's sector discount rank declined from #86 to #101, indicating it is now trading at a less favorable valuation compared to other healthcare companies.
- 2026-09-21 — RVTY's technical positioning has shifted this week as its Relative Strength Index moved from neutral into overbought territory, suggesting the stock has experienced upward momentum. With the company currently trading at a fairly valued assessment, the overbought RSI reading indicates the stock price has risen notably over the recent period. Investors tracking this healthcare sector stock should note this change in momentum indicators alongside the current valuation stance.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is RVTY stock undervalued?
Based on TickrTrends' Forward Fair Value model (updated 2026-10-19), RVTY is trading at more than a 25% premium to estimated fair value and screens as overvalued. The exact fair value and discount are available to subscribers.
What is RVTY's TickrTrends verdict?
RVTY's current verdict is Overvalued, refreshed with every weekly Forward Fair Value run.
How does RVTY compare to other Healthcare stocks?
RVTY ranks #86 of 108 Healthcare stocks in TickrTrends' coverage by discount to fair value.
Is RVTY overbought or oversold?
RVTY's 14-day RSI is in neutral territory - neither overbought nor oversold.
Does RVTY pay a dividend?
Yes. RVTY paid $0.21 per share over the last twelve months (3 payments), a 0.14% yield on TickrTrends' last price. The last ex-dividend date was 2026-07-17.
When does RVTY report earnings next?
RVTY's next earnings report is scheduled for 2026-11-03 (pre-market), per the published earnings calendar.
Does RVTY usually beat earnings estimates?
Over its last 8 reported quarters RVTY beat the consensus estimate 8 times and missed 0 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about RVTY?
Of 17 analysts covering RVTY, 5 rate it a buy, 11 a hold and 1 a sell - hold-leaning, with a consensus price target of $148 (-4.0% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.
More in Healthcare
Head-to-head comparisons
RVTY vs ALKS · RVTY vs AZTA · RVTY vs CDNA · RVTY vs CRL · RVTY vs GILD